Is Fluticasone still in shortage in 2026? Get the latest on Fluticasone inhaler availability, pricing, insurance issues, and what patients can do right now.
If you use Fluticasone—whether it's an inhaler for asthma or a prescription nasal spray—the past two years have been a rollercoaster. Since GSK discontinued brand-name Flovent inhalers in January 2024, patients across the country have dealt with stock issues, insurance headaches, and rising costs.
So where do things stand in 2026? Here's a straightforward update on Fluticasone availability, pricing, and what you can do if you're still having trouble getting your medication.
Technically, Fluticasone is not listed as a formal drug shortage on the FDA's drug shortage database as of early 2026. The active ingredient is being manufactured, and generic Fluticasone Propionate HFA inhalers are on the market.
However, the reality on the ground is more complicated. Many patients still report difficulty finding Fluticasone inhalers at their local pharmacy. This isn't a manufacturing shortage in the traditional sense—it's an access disruption driven by:
For a deeper look at why this is happening, read our article on why Fluticasone is so hard to find in 2026.
The root cause traces back to January 1, 2024, when GSK stopped manufacturing Flovent HFA and Flovent Diskus. These brand-name inhalers had been a cornerstone of asthma treatment in the U.S. for more than 20 years.
GSK replaced Flovent with an authorized generic—Fluticasone Propionate HFA—manufactured by Prasco in partnership with Teva. On paper, this should have been a seamless transition. In practice, it was anything but.
The biggest ongoing problem is insurance. Many health plans had Flovent on their formulary, but when the brand was discontinued, they didn't automatically add the authorized generic. Patients who had been getting Flovent with a $35 copay suddenly faced:
GSK's $35/month inhaler cap applies to brand products but not the authorized generic, leaving many patients in a coverage no-man's-land.
With Fluticasone HFA hard to get covered, prescribers increasingly switched patients to alternatives like Arnuity Ellipta (Fluticasone Furoate) or QVAR RediHaler (Beclomethasone). This surge in demand created intermittent supply pressure on those products too.
Here's what you can expect to pay depending on the formulation:
For a complete breakdown of savings strategies, see our guide on how to save money on Fluticasone in 2026.
The inhaled corticosteroid landscape has continued to evolve:
If you need Fluticasone today, here's your action plan:
For more detailed strategies, read our full guide on how to find Fluticasone in stock near you.
The Fluticasone situation in 2026 is improving, but it's not fully resolved. The combination of a major brand discontinuation, slow-moving insurance systems, and pricing complications has created a prolonged disruption that patients are still navigating.
The most important thing is to not go without your controller medication. Stopping an inhaled corticosteroid abruptly can lead to serious asthma flare-ups. If you can't find Fluticasone, work with your doctor to find an alternative, use tools like Medfinder to locate stock, and explore cost-saving options if price is a barrier.
You deserve to breathe easy. Don't let a disrupted supply chain stand in the way.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
